<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02500381</url>
  </required_header>
  <id_info>
    <org_study_id>4045-301</org_study_id>
    <nct_id>NCT02500381</nct_id>
  </id_info>
  <brief_title>Study of SRP-4045 and SRP-4053 in Participants With Duchenne Muscular Dystrophy (DMD)</brief_title>
  <acronym>ESSENCE</acronym>
  <official_title>A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sarepta Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sarepta Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to evaluate the efficacy of SRP-4045 and SRP-4053&#xD;
      compared to placebo in participants with DMD with out-of-frame deletion mutations amenable to&#xD;
      skipping exon 45 and exon 53, respectively.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, placebo-controlled, multi-center study to evaluate the efficacy and&#xD;
      safety of SRP-4045 and SRP-4053. Eligible participants with out-of-frame deletion mutations&#xD;
      amenable to exon 45 or 53 skipping will be randomized to receive once weekly intravenous (IV)&#xD;
      infusions of 30 milligrams/kilograms (mg/kg) SRP-4045 or 30 mg/kg SRP-4053 respectively&#xD;
      (combined-active group) or placebo for up to 96 weeks (the placebo-controlled period of the&#xD;
      trial). This will be followed by an open-label extension period in which all participants&#xD;
      will receive open-label active treatment for 48 weeks (up to Week 144 of study).&#xD;
&#xD;
      The study will enroll approximately 222 participants. Twice as many participants will be&#xD;
      randomized to receive active treatment as will receive placebo (2:1 randomization).&#xD;
&#xD;
      Clinical efficacy will be assessed at regularly scheduled study visits, including functional&#xD;
      tests, such as the 6-minute walk test (6MWT). All participants will undergo a muscle biopsy&#xD;
      at baseline and a second muscle biopsy either at Week 48 or Week 96.&#xD;
&#xD;
      Safety will be assessed through the collection of adverse events (AEs), laboratory tests,&#xD;
      electrocardiograms (ECGs), echocardiograms (ECHOs), vital signs, and physical examinations&#xD;
      throughout the study.&#xD;
&#xD;
      Blood samples will be taken periodically throughout the study to assess the pharmacokinetics&#xD;
      of both drugs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 28, 2016</start_date>
  <completion_date type="Anticipated">April 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Part 1 is double-blind and randomized; Part 2 is open-label.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in the Total Distance Walked During 6MWT at Week 96</measure>
    <time_frame>Baseline, Week 96</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Total Distance Walked During 6MWT at Week 144 (Week 48 of the Open-Label Extension Period)</measure>
    <time_frame>Baseline, Week 144</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Dystrophin Protein Levels Determined by Western Blot at Weeks 48 or 96</measure>
    <time_frame>Baseline, Week 48 or Week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Dystrophin Intensity Levels Determined by Immunohistochemistry (IHC) at Weeks 48 or 96</measure>
    <time_frame>Baseline, Week 48 or Week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant's Ability to Rise Independently From the Floor, as indicated by a North Star Ambulatory Assessment (NSAA) Subscore</measure>
    <time_frame>Week 96, Week 144</time_frame>
    <description>The NSAA is a clinician administered scale that rates the participant's performance on various functional activities. During this assessment, the participant's ability to rise independently from the floor (without external support) will be reported as an NSAA subscore of &quot;2&quot; (without modification) or &quot;1&quot; (Gower's maneuver).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Loss of Ambulation (LOA)</measure>
    <time_frame>Baseline, Week 96, and Week 144</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the NSAA Total Score at Week 96 and Week 144</measure>
    <time_frame>Baseline, Week 96 and Week 144</time_frame>
    <description>The NSAA is a clinician administered scale that rates the participant's performance on various functional activities. During this assessment, participants will be asked to perform 17 different functional activities, including a 10 meter walk/run, rising from a sit to standing, standing on 1 leg, climbing a box step, descending a box step, rising from lying to sitting, rising from the floor, lifting the head, standing on heels, and jumping. Participants will be graded as follows: 2 = achieves goal without any assistance; 1 = modified method but achieves goal independent of physical assistance from another person; and 0 = unable to achieve goal independently. NSAA Total Score ranges from 0 to 34, with a score of 34 implying normal function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Forced Vital Capacity Percent (FVC%) Predicted at Week 96 and Week 144</measure>
    <time_frame>Baseline, Week 96 and Week 144</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">222</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>SRP-4045</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants amenable to exon 45 skipping will receive SRP-4045 IV infusions, weekly, at 30 mg/kg for up to 96 weeks in the double-blinded period. This will be followed by an open-label extension period in which all participants will receive open-label active treatment of SRP-4045 at 30 mg/kg/week IV infusions for 48 weeks (up to Week 144 in the study).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SRP-4053</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants amenable to exon 53 skipping will receive SRP-4053 IV infusions, weekly, at 30 mg/kg for up to 96 weeks in the double-blinded period. This will be followed by an open-label extension period in which all participants will receive open-label active treatment of SRP-4053 at 30 mg/kg/week IV infusions for 48 weeks (up to Week 144 in the study).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo followed by SRP-4045 or SRP-4053</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants amenable to exon 45 or 53 skipping will receive SRP-4045 or SRP-4053 placebo-matching IV infusions, weekly, at 30 mg/kg for up to 96 weeks in the double-blinded period. This will be followed by an open-label extension period in which all participants will receive open-label active treatment of SRP-4045 or SRP-4053 at 30 mg/kg/week IV infusions for 48 weeks (up to Week 144 in the study).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SRP-4045</intervention_name>
    <description>SRP-4045 solution for IV infusion</description>
    <arm_group_label>Placebo followed by SRP-4045 or SRP-4053</arm_group_label>
    <arm_group_label>SRP-4045</arm_group_label>
    <other_name>Casimersen</other_name>
    <other_name>AMONDYS 45</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SRP-4053</intervention_name>
    <description>SRP-4053 solution for IV infusion</description>
    <arm_group_label>Placebo followed by SRP-4045 or SRP-4053</arm_group_label>
    <arm_group_label>SRP-4053</arm_group_label>
    <other_name>Golodirsen</other_name>
    <other_name>VYONDYS 53</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>SRP-4045 or SRP-4053 placebo-matching solution for IV infusion</description>
    <arm_group_label>Placebo followed by SRP-4045 or SRP-4053</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Genotypically confirmed DMD, with genetic deletion amenable to exon 45 or exon 53&#xD;
             skipping&#xD;
&#xD;
          -  Stable dose of oral corticosteroids for at least 24 weeks prior to Week 1, and the&#xD;
             dose is expected to remain constant throughout the study (except for modifications to&#xD;
             accommodate changes in weight).&#xD;
&#xD;
          -  Intact right and left biceps or 2 alternative upper muscle groups&#xD;
&#xD;
          -  Mean 6MWT ≥300 meters and ≤450 meters&#xD;
&#xD;
          -  Stable pulmonary function: forced vital capacity (FVC) ≥50% predicted&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with gene therapy at any time&#xD;
&#xD;
          -  Previous treatment with SMT C1100 within 1 week prior to Week 1 and previous treatment&#xD;
             with PRO045 (BMN 045), PRO053 (BMN 053), or PRO051 (BMN 051) within 24 weeks prior to&#xD;
             Week 1&#xD;
&#xD;
          -  Current or previous treatment with any other experimental treatment within 12 weeks&#xD;
             prior to Week 1&#xD;
&#xD;
          -  Major surgery within 3 months prior to Week 1&#xD;
&#xD;
          -  Presence of other clinically significant illness&#xD;
&#xD;
        Other inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sarepta Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medical Information</last_name>
    <phone>+1 800-690-2003</phone>
    <email>clinicaltrials@sarepta.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Neuromuscular Research Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>David Geffen School of Medicine, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>UC Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital San Diego/ UCSD</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine/Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Connecticut Children's Medical Center</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>NW Florida Clinical Research Group, LLC</name>
      <address>
        <city>Gulf Breeze</city>
        <state>Florida</state>
        <zip>32561</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Center for Integrative Rare Disease Research (CIRDR)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ann and Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Iowa Children's Hospital</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Kansas, Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Louis Children's Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Las Vegas Clinic</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89145</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Rochester Clinical Research Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center (CCHMC)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shriners Hospital for Children</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Medical Center Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of the King's Daughters</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Children's Hospital Melbourne</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jemima Mitchell</last_name>
      <phone>+61399366157</phone>
      <email>jemima.mitchell@rch.org.au</email>
    </contact>
    <investigator>
      <last_name>Monique Ryan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital at Westmead</name>
      <address>
        <city>Westmead</city>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaitlyn Griffin</last_name>
      <phone>+61298450495</phone>
      <email>kaitlyn.griffin@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Michelle Lorentzos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elke De Vos</last_name>
      <phone>+3293321954</phone>
      <email>elke.devos@uzgent.be</email>
    </contact>
    <investigator>
      <last_name>Nicolas Deconinck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Vanden Eynden</last_name>
      <phone>+3216343991</phone>
      <email>anne.vandeneynden@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Liesbeth De Waele, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHR de la Citadelle</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Buscemi</last_name>
      <phone>+3243218322</phone>
      <email>laura.buscemi@chuliege.be</email>
    </contact>
    <investigator>
      <last_name>Laurent Servais, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment Aleksandrovska EAD</name>
      <address>
        <city>Sofia</city>
        <state>Sofia-Grad</state>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanya Dimitrova</last_name>
      <phone>+359889320421</phone>
      <email>taniadimi@abv.bg</email>
    </contact>
    <investigator>
      <last_name>Ivaylo Tarnev, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alberta Childrens Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trevor Rutschmann</last_name>
      <phone>403-955-3192</phone>
      <email>Trevor.Rutschmann@albertahealthservices.com</email>
    </contact>
    <investigator>
      <last_name>Jean Mah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's and Women's Health Centre of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Conrado De Guzman</last_name>
      <phone>(604) 875-2345 xext6834</phone>
      <email>conrado.deguzman@cw.bc.ca</email>
    </contact>
    <investigator>
      <last_name>Kathryn Selby, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gina Bhullar</last_name>
      <phone>(519) 685-8500</phone>
      <phone_ext>55058</phone_ext>
      <email>gina.bhullar@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>Craig Campbell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Eastern Ontario</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosa Ramos</last_name>
      <email>rramos@cheo.on.ca</email>
    </contact>
    <investigator>
      <last_name>Hans Lochmuller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Brno</name>
      <address>
        <city>Brno</city>
        <zip>61300</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lenka Jurikova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice v Motole</name>
      <address>
        <city>Praha</city>
        <zip>15008</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcela Hlozankova</last_name>
      <phone>+420224433367</phone>
      <email>m.hlozankova@centrum.cz</email>
    </contact>
    <investigator>
      <last_name>Jana Haberlová, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet Copenhagen University Hospital</name>
      <address>
        <city>København Ø</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christina Hoi-Hansen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Des Enfants</name>
      <address>
        <city>Toulouse</city>
        <state>Haute-Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Françoise Auriol</last_name>
      <phone>+33534558589</phone>
      <email>auriol.f@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Claude Cances, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Reference Centre for Neuromuscular Diseases</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christelle Peseux</last_name>
      <phone>+33240087880</phone>
      <email>christelle.peseux@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Yann Péréon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Armand Trousseau</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique Duchêne</last_name>
      <phone>+33171738313</phone>
      <email>d.duchene@institut-myologie.org</email>
    </contact>
    <investigator>
      <last_name>Laurent Servais, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regina Rybka Golm</last_name>
      <phone>+49 30 450 66 10 44</phone>
      <email>regina.rybka-golm@charite.de</email>
    </contact>
    <investigator>
      <last_name>Claudia Weiss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinna Seifert</last_name>
      <phone>+4920172385170</phone>
      <email>corinna.seifert@uk-essen.de</email>
    </contact>
    <investigator>
      <last_name>Ulrike Schara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Wider</last_name>
      <phone>+4976127043440</phone>
      <email>sabine.wider@uniklinik-freiburg.de</email>
    </contact>
    <investigator>
      <last_name>David Schorling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IASO Children's Hospital</name>
      <address>
        <city>Maroussi</city>
        <zip>15123</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Konstantinou</last_name>
      <phone>+306931838751</phone>
    </contact>
    <investigator>
      <last_name>Antigone Papavasiliou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ippokratio General Hospital of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54642</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dimitrios Zafeiriou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem Genomikai Medicina és Ritka Betegsegek Intezete</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noemi Toreki</last_name>
      <phone>+3614591492</phone>
      <email>tnoemy@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Maria Judith Molnar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's University Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>D1</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Declan O'Rourke</last_name>
      <phone>353 (1) 8784200</phone>
      <email>declan.orourke@cuh.ie</email>
    </contact>
    <investigator>
      <last_name>Declan O'Rourke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Schneider Children's Medical Center of Israel</name>
      <address>
        <city>Petah Tikvah</city>
        <zip>49102</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ori Raz</last_name>
      <phone>(972) 525-1860 x44</phone>
      <email>orira1@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Yoram Nevo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Ferrara - Arcispedale Sant' Anna</name>
      <address>
        <city>Ferrara</city>
        <zip>44124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernanda Fortunato</last_name>
      <phone>+393465374262</phone>
      <email>frtfnn@unife.it</email>
    </contact>
    <investigator>
      <last_name>Alessanda Ferlini, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Giannina Gaslini</name>
      <address>
        <city>Genoa</city>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Pedemonte, MD</last_name>
      <phone>+3901056362675</phone>
      <email>marinapedemonte@gaslini.org</email>
    </contact>
    <investigator>
      <last_name>Claudio Bruno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Neurologico Carlo Besta</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Pasquariello</last_name>
      <phone>390223942967</phone>
      <email>angela.pasquariello@istituto-besta.it</email>
    </contact>
    <investigator>
      <last_name>Riccardo Masson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario A Gemelli</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariarosaria Vizzino</last_name>
      <phone>+390630158581</phone>
      <email>npi.clinicaltrials@rm.unicatt.it</email>
    </contact>
    <investigator>
      <last_name>Eugenio Mercuri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Centralny Szpital Kliniczny</name>
      <address>
        <city>Warsaw</city>
        <state>Mazowieckie</state>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Kostera-Pruszczyk, MD, PhD</last_name>
      <phone>(+48 22) 599 28 57</phone>
      <email>neurologia1-sekretariat@wum.edu.pl</email>
    </contact>
    <investigator>
      <last_name>Anna Kostera-Pruszczyk, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Maria Mazurkiewicz-Beldzinska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Federal state budget educational institution of higher education &quot;Russian national research medical university n.a. N.I. Pirogov&quot; of Ministry of healthcare of Russian Federation</name>
      <address>
        <city>Moscow</city>
        <zip>125412</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>7 (495) 483-72-50</phone>
      <email>niki@pedklin.ru</email>
    </contact>
    <investigator>
      <last_name>Dmitry Vlodavets, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinic for Neurology and Psychiatry for Children and Youth</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Biljana Milich</last_name>
      <phone>fax +381 11 2645064</phone>
      <email>biljana.milich@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Vedrana Milic Rasic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de La Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nuria Vidal</last_name>
      <phone>+34935537115</phone>
      <email>nvidalf@santpau.cat</email>
    </contact>
    <investigator>
      <last_name>Jorge Diaz Manera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Deu</name>
      <address>
        <city>Barcelona</city>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Garcia</last_name>
      <phone>+34936009733</phone>
      <email>mgarciago@fsjd.org</email>
    </contact>
    <investigator>
      <last_name>Andres Nascimento, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pilar Marti</last_name>
      <phone>+34961244000</phone>
      <email>mapifres@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Nuria Muelas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Drottning Silvias Barn Och Ungdomssjukhus</name>
      <address>
        <city>Göteborg</city>
        <zip>SE-41685</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna-Lena Tulinius</last_name>
      <phone>+46313436069</phone>
      <email>anna-lena.tulinius@vgregion.se</email>
    </contact>
    <investigator>
      <last_name>Mar Tulinius, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Children (Glasgow)</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lain Horrocks</last_name>
      <phone>44 (0)141 451 6527</phone>
      <email>iain.horrocks@ggc.scot.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Lain Horrocks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leeds Teaching Hospitals NHS Trust</name>
      <address>
        <city>Leeds</city>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Rostron</last_name>
    </contact>
    <investigator>
      <last_name>Ann-Marie Childs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alder Hey Childrens Hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Timothy Henderson</last_name>
      <phone>+441512525164</phone>
      <email>Timothy.Henderson@alderhey.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Stefan Spinty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital (GOSH)</name>
      <address>
        <city>London</city>
        <zip>WC1N 1EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hinal Patel</last_name>
      <phone>020 7905 2639</phone>
      <phone_ext>2639</phone_ext>
      <email>hinal.patel@ucl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Francesco Muntoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie Corrall</last_name>
      <phone>+4401912084569</phone>
      <email>valerie.corrall@ncl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Volker Straub, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sithara Ramdas</last_name>
      <phone>44 (0) 1865234188</phone>
      <email>sithara.ramdas@ouh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Sithara Ramdas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 14, 2015</study_first_submitted>
  <study_first_submitted_qc>July 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2015</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Duchenne muscular dystrophy</keyword>
  <keyword>Exon Skipping</keyword>
  <keyword>DMD</keyword>
  <keyword>Exon 53</keyword>
  <keyword>Exon 45</keyword>
  <keyword>Ambulatory</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Duchenne</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

